{
    "clinical_study": {
        "@rank": "114330", 
        "arm_group": [
            {
                "arm_group_label": "Propofol", 
                "arm_group_type": "Active Comparator", 
                "description": "Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil."
            }, 
            {
                "arm_group_label": "Remimazolam 6 mg/kg/hr", 
                "arm_group_type": "Experimental", 
                "description": "Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil."
            }, 
            {
                "arm_group_label": "Remimazolam 12 mg/kg/hr", 
                "arm_group_type": "Experimental", 
                "description": "Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil."
            }
        ], 
        "brief_summary": {
            "textblock": "This phase II study in patients undergoing elective cardiac surgery will evaluate the\n      efficacy, safety, and pharmacokinetics of remimazolam, compared with propofol and\n      sevoflurane, during the induction and maintenance of general anesthesia."
        }, 
        "brief_title": "Remimazolam Phase II Cardiac Anesthesia Study", 
        "condition": "General Anesthesia", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  scheduled for major elective cardiac surgery.\n\n          -  scheduled for mechanical ventilation via tracheal intubation.\n\n        Exclusion Criteria:\n\n          -  thoraco-abdominal replacement of the aorta or other procedure expected to be\n             accompanied by a massive hemorrhage (at least 15% of the circulating blood volume)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937767", 
            "org_study_id": "CNS7056-010"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Remimazolam 6 mg/kg/hr", 
                    "Remimazolam 12 mg/kg/hr"
                ], 
                "intervention_name": "Remimazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Propofol", 
                "intervention_name": "Propofol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Propofol", 
                "intervention_name": "Sevoflurane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Remimazolam 6 mg/kg/hr", 
                    "Remimazolam 12 mg/kg/hr"
                ], 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Remimazolam 6 mg/kg/hr", 
                    "Remimazolam 12 mg/kg/hr"
                ], 
                "intervention_name": "Fentanyl", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Remimazolam 6 mg/kg/hr", 
                    "Remimazolam 12 mg/kg/hr"
                ], 
                "intervention_name": "Rocuronium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Fentanyl", 
                "Propofol", 
                "Sevoflurane", 
                "Remifentanil", 
                "Rocuronium"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leipzig", 
                    "country": "Germany", 
                    "zip": "04289"
                }, 
                "name": "Herzzentrum Leipzig GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU", 
        "overall_official": {
            "affiliation": "Herzzentrum Leipzig", 
            "last_name": "Stefan Probst, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients with successful anesthesia", 
            "safety_issue": "No", 
            "time_frame": "Between the start of study medication and the end of the surgical procedure (up to approx 12 hours)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937767"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Paion UK Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Aptiv Solutions", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Paion UK Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}